Anzeige
Mehr »
Lynx Broker
Login
Montag, 21.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 852009 ISIN: US7170811035 Ticker-Symbol: PFE 
Tradegate
21.10.19
21:55 Uhr
32,700 Euro
0,000
0,00 %
1-Jahres-Chart
PFIZER INC Chart 1 Jahr
5-Tage-Chart
PFIZER INC 5-Tage-Chart
RealtimeGeldBriefZeit
32,600
32,800
22:31
32,600
32,700
22:00

Aktuelle News zur PFIZER Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:35Pfizer gets some encouraging PhIII news on a franchise savior, but is a dosing advantage worth the $295M upfront?3
14:32Opko and Pfizer announce positive results in late-stage trial of human growth hormone treatment5
14:10Opko Health, Inc.: OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational ...7
PFIZER Aktien ab 5,00 US-Dollar handeln - Ohne versteckte Kosten!
FrPfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst5
FrPfizer-Aktie: Neueinschätzung417Charlotte (www.aktiencheck.de) - Pfizer-Aktienanalyse von Analyst Geoff Meacham von BofA Merrill Lynch Research Geoff Meacham, Aktienanalyst von BofA Merrill Lynch Research, bringt im Rahmen einer Aktienanalyse...
► Artikel lesen
FrBMS, Pfizer turn to Fitbit for atrial fibrillation detection18
DoFitbit enlists Pfizer, Bristol-Myers Squibb to bring arrhythmia detection to its fitness trackers16
MiDiabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio309Technavio has been monitoring the global diabetic neuropathy drugs market since 2016 and the market is poised to grow by USD 866.72 million during 2019-2023, progressing at a CAGR of about 6% during...
► Artikel lesen
DiPfizer scrambles to fill void after Teva stops making chemo drug often given to children120
DiPfizer launches 'catfish' counterfeit medicines campaign1
14.10.Pfizer presents positive phase 3 data for abrocitinib in moderate to severe atopic dermatitis6
14.10.ImaginAb, AstraZeneca, Pfizer, Takeda Join To Develop CD8 ImmunoPET Technology620LONDON (dpa-AFX) - ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announced Monday that it has signed a multi-party collaboration deal with AstraZeneca Plc (AZN.L, AZN)...
► Artikel lesen
13.10.Pfizer takes aim at a flagship franchise at Sanofi and Regeneron - and scores a few direct hits42
12.10.Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis1.655-Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study- -Findings follow recent positive top-line results for second abrocitinib Phase 3 pivotal study, JADE MONO-2-...
► Artikel lesen
11.10.Pfizer's Push For Antisense Licensing Is Closely Aligned With Current Target Indications5
10.10.Akcea to license investigative antisense therapy AKCEA-ANGPTL3-LRx to Pfizer7
09.10.Amid next-gen vaccine race, Merck says ex-employee bolted to Pfizer with 'thousands' of key documents13
08.10.Were Hedge Funds Right About Souring on Pfizer?9
08.10.Pfizer pays $250m upfront to Akcea for phase 2 antisense drug5
07.10.Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal5
Seite:  Weiter >>
786 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
62,6,51